This is great news to patients and care-givers. Strong signal, which may not have been anticipated after the AMBASSADOR data. Would have loved to see the PD-L1 neg. population.

Amazing results. Congratulations to Tom and team. Great opportunity to reduce the number of patients being over treated #EAU

🎉 Just received an email from ASCO Communication featuring the article I wrote for CancerDotNet

Grateful for the opportunity to contribute to such an esteemed platform

Check out the article for insights on cancer.net/blog/2024-02/b…

Transformative results of EV-302 nicely summarized in this NEJM Quick Take video!

But how to move forward for mUC now?🤔

Identifying biomarkers of resistance to EV+PEM is key to further improve outcomes for mUC 🔎

The most intuitive biomarker for predicting response/

👏 great summary of UC.

Could not agree more. Disease burden goes away beyond symptom scales. Need to define the topics that shläouldnbe measured in trials

Great point by Tom Powles! Quality of life for #kidneycancer pts is more than assessing symptoms and AEs during clinical trials. We need tools to characterize and define the disease burden that pts experience throughout the course of their disease.

👏 To Markus and Niklas. Phantastic work on EV sensitivity

Cris, this is great. Big👏 to this important work and all your effort to push this project

Excited to present ASCO #GU24 on a patient-centered HRQOL measure #kidneycancer

Mentored by Tom Powles w stellar team Sumanta K. Pal, MD, FASCO Toni Choueiri, MD Laurence Albiges Viraj Master Viktor Grünwald Elizabeth Plimack MD Sarah P. Psutka MD MS Brian Rini, MD

Marking 2 decades of this fantastic symposium

Totally agree with Sebastian. Multimodal therapy is the treatment of choice. Important to build it into our protocols. Not convinced by the maintainence concept either. To me, the impact of the combo +/- surgery is much more appealing

👏 great work on RW-data by Pia Paffenholz from #GUARDIANS network.

What a fantastic, energetic and dynamic team of interdisciplinary young GU oncologists

ESMO - Eur. Oncology A real world evidence of bone or brain mRCC/german multicenter analysis at #ESMO23 It was a great pleasure to be part of it. Big thanks to Pia Paffenholz

Totally agree. We had a similar observation in #NIVOSWITCH . 3 mo. PFS in pts. on NIVO maintenance in TKI responders. But, enough time to recover from TKI tox

Thanks Viktor Grünwald for highlighting our work on the value of NECTIN4 status to predict EV response at a stellar symposium with Petros Grivas Enrique Grande joaquim bellmunt at ESMO - Eur. Oncology aacrjournals.org/clincancerres/… OncoAlert UroToday.com Clinical Cancer Research Predictive biomarkers are needed !

Absolutely. Great talk by Enrique. We need to understand barriers to treatment.

What a great start to kick off the meeting. Phantastic talk by Petros on current treatment landscape.

Fantastic to join joaquim bellmunt Enrique Grande #Victor 1.00pm at Toledo auditorium Hall 3! Join us for a very informative & interactive session in advanced UC! ESMO - Eur. Oncology OncoAlert Shilpa Gupta Tian Zhang, MD, MHS Uromigos Michiel van der Heijden Daniel Castellano Ignacio Duran Javier Puente Tom Powles

Thank you to Viktor Grünwald of Uniklinikum Essen for joining us to discuss exciting results from a post hoc analysis of the CLEAR trial in RCC. To hear more from top KOLs like Dr. Gruenwald, follow along on social and check us out at onclive.com ESMO - Eur. Oncology #ESMO23 #kcsm